Frameshift mutations in the

Mycobacterium tuberculosis Rv0678 bedaquiline drug-resistant tuberculosis frameshift

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
24 Oct 2024
Historique:
medline: 24 10 2024
pubmed: 24 10 2024
entrez: 24 10 2024
Statut: aheadofprint

Résumé

Bedaquiline (BDQ) is crucial for the treatment of rifampicin-resistant tuberculosis, yet resistance threatens its effectiveness, mainly linked to mutations in the

Identifiants

DOI: 10.1128/aac.00854-24 PMID: 39445816
pubmed: 39445816
doi: 10.1128/aac.00854-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0085424

Auteurs

J Snobre (J)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
ORCID: 0000-0001-7041-8216

C J Meehan (CJ)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Department of Biosciences, Nottingham Trent University, Nottingham, United Kingdom.

W Mulders (W)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

L Rigouts (L)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
ORCID: 0000-0003-3301-9480

R Buyl (R)

Vrije Universiteit Brussel, Brussels, Belgium.

B C de Jong (BC)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

A Van Rie (A)

Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

O Tzfadia (O)

Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
ORCID: 0000-0002-7096-8063

Classifications MeSH